


## CLAIMS

We claim:

1. A method of treating metabolic bone disease where it is desired to maintain or increase bone mass comprising administering to a patient with said disease an effective amount of 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> having the formula:




2. The method of claim 1 where the disease is senile osteoporosis.
3. The method of claim 1 where the disease is postmenopausal osteoporosis.
4. The method of claim 1 where the disease is steroid-induced osteoporosis.
5. The method of claim 1 where the disease is a low bone turnover osteoporosis.
6. The method of claim 1 where the disease is osteomalacia.
7. The method of claim 1 where the disease is renal osteodystrophy.
8. The method of claim 1 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered orally.

9. The method of claim 1 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered parenterally.

10. The method of claim 1 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered transdermally.

11. The method of claim 1 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered in a dosage of from 0.1 $\mu$ g to 10 $\mu$ g per day.

12. A method of treating psoriasis comprising administering to a patient with psoriasis an effective amount of 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> having the formula:




13. The method of claim 12 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered orally.

14. The method of claim 12 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered parenterally.

15. The method of claim 12 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered transdermally.

16. The method of claim 12 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered topically.

18. A method of treating leukemia, colon cancer, breast cancer or prostate cancer comprising administering to a patient with said disease an effective amount of 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> having the formula:



20. The method of claim 18 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered parenterally.

22. The method of claim 12 wherein 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is administered in a dosage of from about 0.01  $\mu$ g/day to about 10  $\mu$ g/day.

- 18 -

